Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering The Use Of Allocetra™ In Patients Receiving Car T-Cell Therapy
19/04/2023 13:10
April 19 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT
APPLICATION
COVERING THE USE OF ALLOCETRA™ IN PATIENTS RECEIVING CAR T-CELL
THERAPY
* ENLIVEX THERAPEUTICS LTD - EXPECTS THAT THIS NEW PATENT
WILL BE
ISSUED IN UNITED STATES DURING 2023
Source text for Eikon: ID:nGNX92gHkv
Further company coverage: ENLV.TA
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment